What is INTI's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.02B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for INTI?

P/E (TTM) is n/a and 52-week range is $0.04 to $0.12 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s INTI figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for INTI?

The company profile lists revenue (TTM) near $4M, net income (TTM) near $-616M, EPS (TTM) near $-0.02 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Inhibitor Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Tampa, Florida, US, 172.6M shares outstanding, ISIN US45720M1053 when available from company profile and filing metadata.

Inhibitor Therapeutics Inc

$INTI

Health Care · Biotechnology

IR Run Scenarios

$0.10

-2.00%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Inhibitor Therapeutics, Inc. engages in the discovery, development, and commercialization of therapeutics for patients with cancer. The company is headquartered in Tampa, Florida and currently employs 2 full-time employees. The firm is focused on developing and commercializing therapeutics based on already approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery for patients with certain cancers and certain non-cancerous proliferation disorders. Its primary focus is on the development of therapies initially for basal cell carcinoma (BCC), prostate and lung cancers in the United States utilizing itraconazole, a drug approved by the United States Food and Drug Administration (FDA) to treat fungal infections. The firm has developed intellectual property and know-how related to the treatment of cancer patients using itraconazole. The firm's intellectual property in the form of issued United States patents includes treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors, and treatment of lung cancer using hedgehog pathway inhibitors.

Employees

Website

inhibitortx.com/

IPO

1996-03-05

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)